Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa

Diagnostic Microbiology and Infectious Disease

Volumn 29, Issue 2, 1997, Pages 81-86

  Giamarellos Bourboulis, Evangelos J ^b   Grecka, Paraskevi ^b   Giamarellou, Helen ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

AMIKACIN; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CEPHALOSPORINS; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; THIENAMYCINS;

EID: 0030813694     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00123-5     Document Type: Article

References (23)

1. Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ (1989) The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 24(suppl A):311-320.
2. Cappellety DM, Kang SL, Palmer SM, Rybak MJ (1995) Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother 33:1797-1801.
3. Chen HY, Yuan M, Ibrahim-Elmagloul IB, Livermore DM (1995) National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 35:521-534.
4. Chin NX, Neu HC (1989) Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia. Diagn Microbiol Infect Dis 12:343-349.
5. Durand Gasselin B, Leclercq R, Girard Pipau F, Deharvengt MC, Rochant H, Astier A, Duval J, Cordonnier C (1995) Evolution of bacterial susceptibility to antibiotics during a six-year period in a haematology unit. J Hosp Infect 29:19-33.
6. Fujita J, Negayama K, Takigawa K, Yamagishi Y, Kubo A, Yamaji Y, Takahara J (1992) Activity of antibiotics against resistant Pseudomonas aeruginosa. J Antimicrob Chemother 29:539-546.
7. Fung-Tomc J, Huczko E, Kolek B, Thater C, Kessler RE (1991) In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant Gram-negative bacteria. Antimicrob Agents Chemother 35:2652-2654.
8. Giamarellou H, Petrikkos G (1987) Ciprofloxacin interactions with imipenem and amikacin against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 31:959-961.
9. Giamarellou H, Zissis NP, Tagari G, Bouzos J (1984) In vitro synergistic activities of aminoglycosides and new β-lactams against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 25:534-536.
10. Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H (1995) In vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa. J Antimicrob Chemother 38:287-291.
11. Hindler J (1992) Tests to assess bactericidal activity. In Clinical Microbiology Procedures Handbook. Ed, Eisenberg HD. Washington, DC: American Society for Microbiology, pp. 5.16.14-5.16.24.
12. Livermore DM (1992) Interplay of impermeability and chromosomal β-lactamase activity in imipenemresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 36:2046-2048.
13. Mandell GL, Sande MA (1990) Penicillins, cephalosporins, and other β-lactam antibiotics. In: The Pharmacological Basis of Therapeutics, 8th ed. Eds, Goodman Gilman A, Rall TW, Nies AS, Taylor P. New York: Pergamon Press, pp. 1065-1097.
14. Masuda N, Sakagawa E, Ohya S (1995) Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 39: 645-649.
15. McGrath BJ, Lamp KC, Rybak MJ (1993) Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model. Antimicrob Agents Chemother 37:1931-1937.
16. Minami S, Akama M, Araki H, Watanabe Y, Narita H, Iyobe S, Mithuhashi S (1996) Imipenem- and cephem-resistant Pseudomonas aeruginosa carrying plasmids coding for class B β-lactamase. J Antimicrob Chemother 37: 433-444.
17. Mugnier P, Dubrous P, Casin I, Arlet G, Collatz E (1996) TEM-derived extended-spectrum β-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother 40: 2488-2493.
18. Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, Keating MJ, Holmes FA, Carbanillas FF, Elting L (1992) A comparison of imipenem to ceftazidime with or without amikacin as empirical therapy in febrile neutropenic patients. Arch Intern Med 152:282-291.
19. Sande ME, Mandell GL (1990) The aminoglycosides. In The Pharmacological Basis of Therapeutics, 8th Ed. Eds, Goodman Gilman A, Rail TW, Nies AS, Taylor P. New York: Pergamon Press, pp. 1098-1116.
20. Senda K, Arakawa Y, Nakashima K, Ito H, Ichiyama S, Shimokata K, Kato N, Ohta M (1996) Multifocal out-breaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrob Agents Chemother 40: 349-353.
21. Solberg CO, Sjursen H (1995) Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin. J Antimicrob Chemother 36(suppl A):157-166.
22. Trias J, Nikaido H (1990) Outer membrane protein D2 catalyzed faciliated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 34:52-57.
23. Woods GL, Washington JA (1995) Antibacterial susceptibility tests: Dilution and disk diffusion methods. In Manual of Clinical Microbiology, 6th Ed. Eds, Murray PR, Baron EJ, Pfaller MA, Tehover FC, Yolken RH, Washington, DC: American Society for Microbiology Press, pp. 1327-1341.